Scientists from St. Jude Children’s Research Hospital and University Health Network’s Princess Margaret Cancer Centre have discovered that the stage at which developing B-cells turn cancerous significantly influences treatment outcomes for pediatric B-cell acute lymphoblastic leukemia (B-ALL). Their findings, published in Nature Cancer, could lead to better risk assessment and personalized therapies for patients.
The researchers created a detailed single-cell reference atlas of normal human B-cell development and compared it with data from B-ALL patients. They found that leukemic cells can arise at various stages of B-cell maturation, not just the previously assumed pro- to pre-B cell stage. Some cases involved more mature cells, while others originated from earlier hematopoietic progenitor cells.
The study revealed that less mature leukemic cells retain the ability to switch lineages, a potential mechanism for drug resistance. To quantify this, the team developed a “multipotency score,” which accurately predicted patient outcomes in independent samples. This tool could serve as a new biomarker for risk stratification.
Dr. Charles Mullighan, the study’s corresponding author, emphasized the clinical relevance: “With genomic data from patients, we now better understand which subtypes are prone to resistance or therapy failure, adding a critical layer for risk assessment.”
Dr. John Dick, a collaborator, highlighted the broader impact: “This study fills a gap in our knowledge of B-cell development and links these insights to clinically actionable leukemia subtypes.”
The findings pave the way for improved diagnostics and targeted therapies, offering hope for more effective treatment strategies in pediatric B-ALL.
Add comment